Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics, Inc. reported a net loss of $83.9 million for fiscal year 2025, with no revenue generated during the period. The company's operations resulted in an operating loss of $89.8 million, driven primarily by research and development expenses of $69.5 million and general and administrative costs of $20.3 million. Other income, primarily from interest income of $6.0 million, partially offset the operating loss. The company ended the year with total assets of $130.9 million, including $26.7 million in cash and cash equivalents and $81.3 million in short-term investments. Total liabilities stood at $21.0 million, resulting in stockholders' equity of $110.0 million. Net cash used in operating activities was $76.8 million, while investing activities provided $63.4 million primarily from investment maturities. The company's financial position reflects its continued investment in research and development activities as a clinical-stage biotechnology company.

Key Takeaways